Reversal of pathological pain through specific spinal GABAA receptor subtypes
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inflammatory diseases and neuropathic insults are frequently accompanied by severe and debilitating pain, which can become chronic and often unresponsive to conventional analgesic treatment. A loss of synaptic inhibition in the spinal dorsal horn is considered to contribute significantly to this pain pathology. Facilitation of spinal gamma-aminobutyric acid (GABA)ergic neurotransmission through modulation of GABA(A) receptors should be able to compensate for this loss. With the use of GABA(A)-receptor point-mutated knock-in mice in which specific GABA(A) receptor subtypes have been selectively rendered insensitive to benzodiazepine-site ligands, we show here that pronounced analgesia can be achieved by specifically targeting spinal GABA(A) receptors containing the alpha2 and/or alpha3 subunits. We show that their selective activation by the non-sedative ('alpha1-sparing') benzodiazepine-site ligand L-838,417 (ref. 13) is highly effective against inflammatory and neuropathic pain yet devoid of unwanted sedation, motor impairment and tolerance development. L-838,417 not only diminished the nociceptive input to the brain but also reduced the activity of brain areas related to the associative-emotional components of pain, as shown by functional magnetic resonance imaging in rats. These results provide a rational basis for the development of subtype-selective GABAergic drugs for the treatment of chronic pain, which is often refractory to classical analgesics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Also, in contrast to morphine, no analgesic tolerance occurred in rats after a 9-day treatment with the α 2/3 subtype GABAA receptor positive allosteric modulator L838,417 using a model of neuropathic pain [157].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [157]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,831
Melzack, R., & Wall, P. D. (1965) · Science · doi:10.1126/science.150.3699.971 · Cited by 11,090
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Bennett, G. J., & Xie, Y.-K. (1988) · Pain · doi:10.1016/0304-3959(88)90209-6 · Cited by 5,376
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Hargreaves, K., Dubner, R., Brown, F., Flores, C., & Joris, J. (1988) · Pain · doi:10.1016/0304-3959(88)90026-7 · Cited by 5,135
Neuronal plasticity: Increasing the gain in pain
Woolf, C. J., & Salter, M. W. (2000) · Science · doi:10.1126/science.288.5472.1765 · Cited by 3,781
Dubuisson, D., & Dennis, S. G. (1977) · Pain · doi:10.1016/0304-3959(77)90130-0 · Cited by 2,524
RARE imaging: A fast imaging method for clinical MR
Hennig, J., Nauerth, A., & Friedburg, H. (1986) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910030602 · Cited by 2,081
BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain
Coull, J. A. M., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel, C., Salter, M. W., & De Koninck, Y. (2005) · Nature · doi:10.1038/nature04223 · Cited by 1,965
Cited by
Items 101–200 of 441
Glycine inhibitory dysfunction turns touch into pain through astrocyte-derived D-serine
Miraucourt, L. S., Peirs, C., Dallel, R., & Voisin, D. L. (2011) · Pain · doi:10.1016/j.pain.2011.02.021 · Cited by 74
“This, together with convergent findings by others [2,10,11,20, 21,58], emphasized the role of disinhibition in pathological pain.”
BackgroundSpinal excitatory mechanisms of pathological pain
Kuner, R. (2015) · Pain · doi:10.1097/j.pain.0000000000000118 · Cited by 61
Bali, K. K., Selvaraj, D., Satagopam, V., Lu, J., Schneider, R., & Kuner, R. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302797 · Cited by 68
Bell, D. C., & Dallas, M. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13916 · Cited by 59
“GABAA and GABAB receptors have become relevant targets in pain therapeutics following a number of studies (Enna and McCarson, 2006; Knabl et al., 2008; Ji and Neugebauer, 2011; Kahle et al., 2016).”
BackgroundInfluentialRech, J., Heß, A., Finzel, S., Kreitz, S., Sergeeva, M., Englbrecht, M., Doerfler, A., Saake, M., & Schett, G. A. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37761 · Cited by 60
“3) and our own software, MagnAn, as previously described in detail (4,17).”
Chloride – The Underrated Ion in Nociceptors
Wilke, B. U., Kummer, K. K., Leitner, M. G., & Kress, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00287 · Cited by 65
Perucca, E., White, H. S., & Bialer, M. (2023) · CNS Drugs · doi:10.1007/s40263-023-01025-4 · Cited by 72
Zhang, Z., Wang, X., Wang, W., Lu, Y.-G., & Pan, Z. Z. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.086496 · Cited by 63
“It has been shown that both neuropathic and inflammatory pain involves the mechanism of impaired GABA synaptic inhibition in the spinal dorsal horn where a pain signal is transmitted to the brain for pain perception (Knabl et al., 2008; Costigan et al., 2009).”
BackgroundChen, X., van Gerven, J., Cohen, A. F., & Jacobs, G. E. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0185-5 · Cited by 60
Waldvogel, H. J., Baer, K., Eady, E. K., Allen, K. L., Gilbert, R. T., Möhler, H., Rees, M. I., Nicholson, L. F. B., & Faull, R. L. M. (2009) · The Journal of Comparative Neurology · doi:10.1002/cne.22212 · Cited by 65
“Furthermore, recent data have demonstrated the involvement of specific spinal GABAAR subtypes in chronic pain (Knabl et al., 2008) and in patients with temporal lobe epilepsy, in whom GABAAR 3 subunit staining was decreased remarkably in the neocortex (Loup et al., 2006), whereas the GABAAR…”
BackgroundSelf-citationViguier, F., Michot, B., Kayser, V., Bernard, J., Vela, J. M., Hamon, M., & Bourgoin, S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.023 · Cited by 63
The α5 subunit containing GABAA receptors contribute to chronic pain
Bravo‐Hernández, M., Corleto, J. A., Barragán‐Iglesias, P., González‐Ramírez, R., Pineda-Farías, J. B., Felix, R., Calcutt, N. A., Delgado‐Lezama, R., Maršala, M., & Granados‐Soto, V. (2015) · Pain · doi:10.1097/j.pain.0000000000000410 · Cited by 61
Cao, T., Chen, H., Huang, W., Xu, S., Liu, P., Zou, W., Pang, M., Xu, Y., Bai, X., Liu, B., et al. (2022) · Theranostics · doi:10.7150/thno.72015 · Cited by 56
GABAA receptor modulation by piperine and a non-TRPV1 activating derivative
Khom, S., Strommer, B., Schöffmann, A., Hintersteiner, J., Baburin, I., Erker, T., Schwarz, T., Schwarzer, C., Zaugg, J., Hamburger, M. O., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.017 · Cited by 55
Vuilleumier, P. H., Besson, M., Desmeules, J., Arendt-Nielsen, L., & Curatolo, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0043896 · Cited by 53
Anseloni, V. C. Z., & Gold, M. S. (2008) · Journal of Pain · doi:10.1016/j.jpain.2008.03.004 · Cited by 53
Werdehausen, R., Mittnacht, S., Bee, L., Minett, M. S., Armbruster, A., Bauer, I., Wood, J. N., Hermanns, H., & Eulenburg, V. (2015) · Pain · doi:10.1097/j.pain.0000000000000206 · Cited by 55
“has largely failed, in part due to an ubiquitary abundance of GABAA receptors, 51 although a1-sparing GABAA receptor agonists have yet to be tested in patients.(30) Although there are”
BackgroundAtack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52
Thermal Hyperalgesia via Supraspinal Mechanisms in Mice Lacking Glutamate Decarboxylase 65
Kubo, K., Nishikawa, K., Ishizeki, J., Hardy-Yamada, M., Yanagawa, Y., & Saito, S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156034 · Cited by 55
“(Knabl et al., 2008) should be able to compensate for loss of”
BackgroundThe Expanding Therapeutic Potential of Neuronal KCC2
Tang, B. L. (2020) · Cells · doi:10.3390/cells9010240 · Cited by 54
“Although a GABA agonist L-838,417 [67] (which did not promote functional recovery) also reduced c-Fos-positive neurons in the dorsal horn, it did not elevate c-Fos in the intermediate zones and the ventral region.”
BackgroundSpinal cord retinoic acid receptor signaling gates mechanical hypersensitivity in neuropathic pain
Cao, B., Scherrer, G., & Chen, L. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.027 · Cited by 61
Peripheral and spinal GABAergic regulation of incisional pain in rats
Reichl, S. U., Augustin, M., Zahn, P. K., & Pogatzki-Zahn, E. M. (2011) · Pain · doi:10.1016/j.pain.2011.09.028 · Cited by 51
“The corresponding GABA-A receptor, a ligand-gated chloride channel, contains different alpha subunits, including a1, a2, a3, and a5, and is evenly distributed in the dorsal horn of the spinal cord [25,29,33].”
BackgroundInfluentialMunro, G., Erichsen, H. K., Rae, M. G., & Mirza, N. R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.017 · Cited by 55
Uddin, M. S., Mamun, A. A., Rahman, M. A., Kabir, M. T., Alkahtani, S. H., Alanazi, I. S., Perveen, A., Ashraf, G. M., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00478 · Cited by 53
GABAA receptor modulation: Potential to deliver novel pain medicines?
Munro, G., Hansen, R. B., & Mirza, N. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.070 · Cited by 50
Central Hypersensitivity in Chronic Musculoskeletal Pain
Curatolo, M., & Arendt‐Nielsen, L. (2015) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2014.12.002 · Cited by 57
Akbar, S., Subhan, F., Karim, N., Shahid, M. M., Ahmad, N., Ali, G., Mahmood, W., & Fawad, K. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.017 · Cited by 49
Poe, M. M., Methuku, K. R., Li, G., Verma, A. R., Teske, K. A., Stafford, D. C., Arnold, L. A., Cramer, J. W., Jones, T. M., Cerne, R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01332 · Cited by 53
Chen, X., Jacobs, G. E., de Kam, M., Jaeger, J., Lappalainen, J., Maruff, P. T., Smith, M. A., Cross, A. J., Cohen, A. F., & van Gerven, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12413 · Cited by 54
Aouad, M., Charlet, A., Rodeau, J.-L., & Poisbeau, P. (2009) · Pain · doi:10.1016/j.pain.2009.08.001 · Cited by 47
“of exogenous modulators targeting specific GABAARs within the nociceptive system [19], there are growing lines of evidence indicating that the antinociceptive properties of local endogenous neuroactive neurosteroids could be used as an alternative strategy [28].”
BackgroundPaul, J., Yévenes, G. E., Benke, D., Lio, A. D., Ralvenius, W. T., Witschi, R., Scheurer, L., Cook, J. M., Rudolph, U., Fritschy, J.-M., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.221 · Cited by 47
“Studies testing these newly developed compounds revealed significant analgesic or antihyperalgesic properties in rodent pain models (Di Lio et al, 2011; Knabl et al, 2008; Nickolls et al, 2011, for a review see Zeilhofer et al, 2012).”
BackgroundInfluentialSelf-citationGABAA Receptor α Subunits Differentially Contribute to Diazepam Tolerance after Chronic Treatment
Vinkers, C. H., van Oorschot, R., Nielsen, E. Ø., Cook, J. M., Hansen, H. H., Groenink, L., Olivier, B., & Mirza, N. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043054 · Cited by 47
Restoring the Spinal Pain Gate
Zeilhofer, H. U., Ralvenius, W. T., & Acuña, M. A. (2015) · Advances in pharmacology · doi:10.1016/bs.apha.2014.11.007 · Cited by 50
“…and α5GABAARs (15–32%, relative to diazepam; McKernan et al., 2000), was tested in several rodent pain models where it was not sedative but active against inflammatory and neuropathic hyperalgesia (Knabl et al., 2008; Nickolls et al., 2011) and formalin-induced nociception (Hofmann et al., 2012).”
Self-citationCannabinoids in Chronic Pain: Therapeutic Potential Through Microglia Modulation
van den Hoogen, N. J., Harding, E. K., Davidson, C. E. D., & Trang, T. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.816747 · Cited by 45
mir-500-Mediated GAD67 Downregulation Contributes to Neuropathic Pain
Huang, Z.-Z., Wei, J., Ouyang, H., Li, D., Xu, T., Wu, S.-L., Zhang, X., Liu, C., Ma, C., & Xin, W. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0646-16.2016 · Cited by 45
Psychotropic Drugs for the Management of Chronic Pain and Itch
Belinskaia, D. A., Belinskaia, M. A., Barygin, O. I., Vanchakova, N. P., & Shestakova, N. N. (2019) · Pharmaceuticals · doi:10.3390/ph12020099 · Cited by 49
“Synthetic compound L-838,417 is an agonist of the α1, α2, and α3 subunits and an antagonist of the α5 subunit of the GABAAR; it was shown that this drug has the ability to reduce neuropathic pain in animal models without an addictive effect [85].”
BackgroundPeng, H., Chen, G., Lee, S., Lai, C., Chiu, C.-H., Cheng, C.-L., Chang, Y.-S., Hsieh, M., Tung, K., & Lin, T.-B. (2009) · Pain · doi:10.1016/j.pain.2008.12.023 · Cited by 51
“On the other hand, a recent study using GABAAR point-mutated mice demonstrated a pronounced analgesic effect by specifically targeting spinal GABAAR containing the a2 and a3 subunits [32].”
The Legacy of the Benzodiazepine Receptor
Möhler, H. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.10.008 · Cited by 43
Self-citationLewter, L. A., Fisher, J. L., Siemian, J. N., Methuku, K. R., Poe, M. M., Cook, J. M., & Li, J.-X. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00447 · Cited by 43
Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity
Fan, H.-R., Du, W., Zhu, T., Wu, Y., Liu, Y., Wang, Q., Wang, Q., Gu, X., Shan, X., Deng, S., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.031 · Cited by 45
“Collectively, therapeutic potentials by virtue of negative modulators of GABAARs for neuropsychiatric disorders [6, 29, 64], including schizophrenia, are far underestimated.”
BackgroundNeuronal Glutamate and GABAA Receptor Function in Health and Disease
Moult, P. R. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371317 · Cited by 49
Characterization of incisional and inflammatory pain in rats using functional tools of MRI
Amirmohseni, S., Segelcke, D., Reichl, S. U., Wachsmuth, L., Görlich, D., Faber, C., & Pogatzki-Zahn, E. M. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.11.052 · Cited by 43
PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia
Jiang, C., Wang, Z., Donnelly, C. R., Wang, K., Andriessen, A. S., Tao, X., Matsuda, M., Zhao, J., & Ji, R. (2020) · iScience · doi:10.1016/j.isci.2020.101570 · Cited by 44
Emerging drug targets for pain treatment
Li, J., & Zhang, Y. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.017 · Cited by 44
Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
Ralvenius, W. T., Neumann, E., Pagani, M., Acuña, M. A., Wildner, H., Benke, D., Fischer, N., Rostaher, A., Schwager, S., Detmar, M. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05709-0 · Cited by 43
Self-citationGABA(A) receptor-targeted drug development -New perspectives in perioperative anesthesia
Antkowiak, B., & Rammes, G. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1599356 · Cited by 44
“benzodiazepines in current clinical use [19,105,106].”
BackgroundCao, J., Yang, X. Z., Liu, Y., Suo, Z., Shi, L., Zheng, C., Yang, H., Li, S., & Hu, X. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.034 · Cited by 40
Stamenić, T. T., Poe, M. M., Rehman, S., Santrač, A., Divović, B., Scholze, P., Ernst, M. C., Cook, J. M., & Savić, M. M. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.016 · Cited by 42
“Moreover, the administration of L-838,417, a ligand with significant, but comparably small efficacy at α2-, α3- and α5GABAARs, did not cause deficits in rotarod performance in rats (Knabl et al., 2008) or mice (McKernan et al., 2000).”
BackgroundPhotosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator
Gurrell, R., Gorman, D. N., Whitlock, M., Ogden, A. G., Reynolds, D. S., DiVentura, B. D., Abou-Khalil, B. W., Gelfand, M. A., Pollard, J., Hogan, R. E., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007271 · Cited by 40
Neuropathic pain modeling: Focus on synaptic and ion channel mechanisms
Bouali‐Benazzouz, R., Landry, M., Benazzouz, A., & Fossat, P. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102030 · Cited by 42
Mild KCC2 Hypofunction Causes Inconspicuous Chloride Dysregulation that Degrades Neural Coding
Doyon, N., Prescott, S. A., & Koninck, Y. D. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00516 · Cited by 43
“This is important because disinhibition caused by an arbitrarily applied shift in EGABA can, depending on the degree of change, be offset by an increase in ginh (Prescott et al., 2006; Knabl et al., 2008; Asiedu et al., 2010; Doyon et al., 2011).”
BackgroundRegulation of GABAA Receptor Dynamics by Interaction with Purinergic P2X2 Receptors
Shrivastava, A. N., Triller, A., Sieghart, W., & Sarto‐Jackson, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165282 · Cited by 43
Inhibitory regulation of the pain gate and how its failure causes pathological pain
Price, T. J., & Prescott, S. A. (2015) · Pain · doi:10.1097/j.pain.0000000000000139 · Cited by 37
Functional Synaptic Integration of Forebrain GABAergic Precursors into the Adult Spinal Cord
Etlin, A., Braz, J. M., Kuhn, J., Wang, X., Hamel, K. A., Llewellyn‐Smith, I. J., & Basbaum, A. I. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2301-16.2016 · Cited by 38
Owen, R. M., Blakemore, D. C., Cao, L., Flanagan, N. J., Fish, R. L., Gibson, K. R., Gurrell, R., Huh, C. W., Kammonen, J., Mortimer‐Cassen, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00322 · Cited by 53
Hossaini, M., Duraku, L. S., Sarac, C., Jongen, J. L. M., & Holstege, J. C. (2010) · Pain · doi:10.1016/j.pain.2010.07.023 · Cited by 37
“Further, it was recently shown that selective activation of GABA(A) receptors containing the a2 and/or a3 subunits [26] leads to pronounced nociceptive inhibition.”
BackgroundAkbar, S., Subhan, F., Shahid, M. M., Wadood, A., Shahbaz, N., Farooq, U., Ayaz, M., & Raziq, N. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172972 · Cited by 36
Li, J., Zhang, L., Chu, X., Shen, Y., Lin, Y., Zhang, Y., Wu, H., Chang, L., Zhang, Y., Chen, R., et al. (2021) · Theranostics · doi:10.7150/thno.58364 · Cited by 36
Extrasynaptic GABAA Receptors in the Brainstem and Spinal Cord: Structure and Function
Delgado‐Lezama, R., Loeza‐Alcocer, E., Andrés, C., Aguilar, J., Guertin, P. A., & Felix, R. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319240013 · Cited by 39
Medicinal Chemistry of ρ GABACReceptors
Ng, C. K. L., Kim, H.-L., Gavande, N. S., Yamamoto, I., Kumar, R., Mewett, K. N., Johnston, G. A. R., Hanrahan, J. R., & Chebib, M. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.10.286 · Cited by 36
Vasović, D., Divović, B., Treven, M., Knutson, D. E., Steudle, F., Scholze, P., Obradović, A. L., Fabjan, J., Brkovic, B. M. B., Sieghart, W., et al. (2019) · European Journal of Pain · doi:10.1002/ejp.1365 · Cited by 37
“Positive allosteric modulators (PAMs) that preferentially modulate α2βγ2 GABAA receptor subtypes are able to elicit a systemic analgesic effect (Knabl et al., 2008; Rudolph & Knoflach, 2011).”
Kolodziej, A., Lippert, M., Angenstein, F., Neubert, J., Pethe, A., Grosser, O. S., Amthauer, H., Schroeder, U. H., Reymann, K. G., Scheich, H., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.09.023 · Cited by 34
Besson, M. J., Matthey, A., Daali, Y., Poncet, A., Vuilleumier, P. H., Curatolo, M., Zeilhofer, H. U., & Desmeules, J. A. (2015) · Pain · doi:10.1097/01.j.pain.0000460331.33385.e8 · Cited by 35
“24,28,49,50 Benzodiazepine site agonist-sensitive GABAA receptors contain 1 or 2 of the following a subunits: a1, a2, a3, or a5, together with 2 b subunits and 1 g2 subunit in a 2:2:1 stoichiometry.2,3 Work in GABAA receptor point-mutated mice has shown that the sedative action of BDZs is mainly mediated by GABAA rece…”
BackgroundResultInfluentialSelf-citationMirogabalin and emerging therapies for diabetic neuropathy
Javed, S., Alam, U., & Malik, R. A. (2018) · Journal of Pain Research · doi:10.2147/jpr.s145999 · Cited by 36
“modulators are developed as a potential new therapeutic area for chronic neuropathic pain.(39,40) More recently, it has”
Antkowiak, B., & Rudolph, U. (2016) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000358 · Cited by 42
“However, it is known that in rodents, intrathecally applied and thus primarily spinally acting benzodiazepines have an antihyperalgesic action in a variety of pain models, including models of inflammatory and of neuropathic pain [21].”
BackgroundSelf-citationAttenuation of Neuropathic Pain by Inhibiting Electrical Synapses in the Anterior Cingulate Cortex
Chen, Z., Shen, F.-Y., Jiang, L., Zhao, X., Shen, X., Zhong, W., Liu, S., Wang, Z.-R., & Wang, Y. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000942 · Cited by 36
Ibrahim, N. M., Abdelhameed, K. M., Kamal, S. M., Khedr, E. M., & Kotb, H. I. (2017) · Pain Medicine · doi:10.1093/pm/pnx087 · Cited by 34
Assessment of Pain and Itch Behavior in a Mouse Model of Neurofibromatosis Type 1
O’Brien, D. E., Brenner, D., Gutmann, D. H., & Gereau, R. W. (2013) · Journal of Pain · doi:10.1016/j.jpain.2013.01.770 · Cited by 36
“If GABAergic inhibition is increased in the spinal cord or midbrain in Nf16 mice, the hypothesized pathological pain in Nf16mice may be prevented since GABAA receptor activation in spinal and midbrain structures relieves hyperalgesia in mice.(25,35,47) Similarly, since inhibition of itch requires spinal cord dorsal ho…”
de Lucas, A. G., Ahring, P. K., Larsen, J. S., Rivera-Arconada, I., Lopez-Garcia, J. A., Mirza, N. R., & Munro, G. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.010 · Cited by 32
“These findings are consistent both with the low expression of the a5 subunit in the spinal cord [15], and data from a5 point mutated knock-in mice which indicate that this subtype has a minor contribution to the hypersensitivity associated with inflammatory injury [4].”
BackgroundMethodResultInfluentialRalvenius, W. T., Acuña, M. A., Benke, D., Matthey, A., Daali, Y., Rudolph, U., Desmeules, J. A., Zeilhofer, H. U., & Besson, M. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.004 · Cited by 34
“…open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). in the spinal cord through locally applied DZP reverses pathologically increased pain sensitivity (hyperalgesia) in rodent models of chronic inflammatory and neuropathic pain (Knabl et al., 2008).”
InfluentialSelf-citationPérez-Sánchez, J., Lorenzo, L.-É., Lecker, I., Zurek, A. A., Labrakakis, C., Bridgwater, E. M., Orser, B. A., Koninck, Y. D., & Bonin, R. P. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23981 · Cited by 36
“Overall, our findings are in agreement with other studies using pharmacological approaches that identify an overall antinociceptive effect of a5GABAAR activity (Knabl et al., 2008; Knabl et al., 2009; Ralvenius et al., 2015).”
BackgroundResultZhang, J., Yu, J. T., Kannampalli, P., Nie, L., Meng, H., MEDDA, B. K., Shaker, R., Sengupta, J. N., & Banerjee, B. (2017) · Pain · doi:10.1097/j.pain.0000000000001057 · Cited by 34
“The loss of GABAergic inhibition in painsignaling pathways has been proposed as one of the primary mechanisms for pain-induced hyperalgesia and appear to play a key role in the development of acute to chronic pain.(11,19) Impaired GABAergic inhibition in the spinal cord has been reported to contribute to neuropathic p…”
Auta, J., Impagnatiello, F., Kadriu, B., Guidotti, A., & Costa, E. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.002 · Cited by 34
“A recent report by Knabl et al (2008) demonstrated that long-term treatment with L-838,417, a non-sedating α1-sparing benzodiazepine recognition site ligand but a partial agonist at α2-, α3- and α5-containing GABAA receptors fail to show tolerance to its analgesic effect.”
BackgroundSpinal Cord Injury Provoked Neuropathic Pain and Spasticity, and Their GABAergic Connection
Bhagwani, A., Chopra, M., & Kumar, H. (2022) · Neurospine · doi:10.14245/ns.2244368.184 · Cited by 39
Subtype-selective GABAA receptor mimetics—novel antihyperalgesic agents?
Zeilhofer, H. U., Witschi, R., & Hösl, K. M. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0454-3 · Cited by 37
“Published evidence suggests that physical dependence does not occur with several α1-sparing agents (L-838,417, SL651498, and TPA023) [30] and at least in the case of L-838,417, tolerance against the antihyperalgesic effect was completely absent during a 9-day treatment period—in striking contrast to morphine, which ha…”
BackgroundInfluentialSelf-citationInvolvement of glycine receptor α1 subunits in cannabinoid-induced analgesia
Lu, J.-P., Fan, S., Zou, G., Hou, Y., Pan, T., Guo, W., Yao, L., Du, F., Homanics, G. E., Liu, D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.041 · Cited by 38
Gurrell, R., Dua, P., Feng, G., Sudworth, M., Whitlock, M., Reynolds, D. S., & Butt, R. P. (2018) · Pain · doi:10.1097/j.pain.0000000000001267 · Cited by 31
State-of-the-art pharmacotherapy for diabetic neuropathy
Azmi, S., Alam, U., Burgess, J., & Malik, R. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1812578 · Cited by 32
Hama, A. T., & Sagen, J. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.03.015 · Cited by 31
“Clinical studies with a GABAA receptor agonist would directly address the role of this receptor in SCI and other pain states (Knabl et al., 2008).”
BackgroundPuri, J., Vinothini, P., Reuben, J. M., Bellinger, L. L., Ailing, L., Peng, Y. B., & Kramer, P. R. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.059 · Cited by 32
“In the spinal cord, neuronal inhibition will occur after blockade or deletion of GABAA receptor subunits α2, α3 and α5 (Munro et al., 2008; Knabl et al., 2008; Knabl et al., 2009), and a recent study demonstrated presynaptic inhibition resulting from primary afferent depolarization (PAD) required…”
BackgroundModulation of Glycine Receptor Function by the Synthetic Cannabinoid HU210
Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., Karst, M., Dengler, R., Haeseler, G., & Ahrens, J. (2009) · Pharmacology · doi:10.1159/000209291 · Cited by 33
Analgesia for Sheep in Commercial Production: Where to Next?
Small, A. H., Fisher, A. D., Lee, C., & Colditz, I. G. (2021) · Animals · doi:10.3390/ani11041127 · Cited by 37
An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
Chen, X., de Haas, S., de Kam, M., & van Gerven, J. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/134523 · Cited by 41
“Hindawi Publishing Corporation Advances in Pharmacological Sciences Volume 2012, Article ID 134523, 10 pages doi:10.1155/2012/134523 Review Article”
BackgroundInfluentialDifferential Modulation of Nociceptive versus Non-Nociceptive Synapses by Endocannabinoids
Higgins, A. S., Yuan, S., Wang, Y., & Burrell, B. D. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-26 · Cited by 35
“GABA-mediated depolarization has been shown to increase synaptic transmission in both the brain and the spinal cord circuits [32-35], although there are also instances when GABA-mediated depolarization inhibits synaptic transmission via current shunts or Na channel inactivation [31,35].”
BackgroundChen, X., Jacobs, G. E., de Kam, M. L., Jaeger, J., Lappalainen, J., Maruff, P. T., Smith, M. A., Cross, A. J., Cohen, A. F., & van Gerven, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000251 · Cited by 31
Smith, K. M., Boyle, K. A., Mustapa, M., Jobling, P., Callister, R. J., Hughes, D. I., & Graham, B. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.058 · Cited by 37
“Importantly, both GABA and glycine mediate fast inhibitory synaptic inhibition in the DH, and experimental manipulation of each transmitter can alter sensory processing and either generate or alleviate pain-related behaviors in rodent pain models (Ishikawa et al., 2000; Knabl et al., 2008).”
BackgroundAnalgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans
van Amerongen, G., Siebenga, P. S., Gurrell, R., Dua, P., Whitlock, M., Gorman, D. N., Okkerse, P., Hay, J. L., Butt, R. P., & Groeneveld, G. J. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.006 · Cited by 31
Restoring ionotropic inhibition as an analgesic strategy
Bonin, R. P., & Koninck, Y. D. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.047 · Cited by 34
Chaumont‐Dubel, S., André, C., Perrais, D., Boué‐Grabot, É., Taly, A., & Garret, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470807 · Cited by 33
Nickolls, S. A., Mace, H., Fish, R. L., Edye, M. E., Gurrell, R., Ivarsson, M., Pitcher, T., Tanimoto-Mori, S., Richardson, D. S., Sweatman, C., et al. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/608912 · Cited by 34
“This was also in contrast to data previously published by other authors in the CCI model of neuropathic pain [4].”
BackgroundResultInfluentialCurcumol allosterically modulates GABA(A) receptors in a manner distinct from benzodiazepines
Liu, Y., Fan, H.-R., Ding, J., Huang, C., Deng, S., Zhu, T., Xu, T., Ge, W., Li, W., & Li, F. R. (2017) · Scientific Reports · doi:10.1038/srep46654 · Cited by 29
Nimmich, M. L., Heidelberg, L. S., & Fisher, J. L. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.01.003 · Cited by 33
Chen, Y., Zhu, B., Zhang, H., Ding, D., Liu, X., & Guo, S. (2014) · Reproductive Sciences · doi:10.1177/1933719113518984 · Cited by 28
“Indeed, supraspinal GABAergic inhibition, usually through modulation of specific GABAA receptor subtypes, plays an important role in neuronal hyperexcitability and spinal/supraspinal nociceptive neurons.(18,19) We have previously shown that mice with induced adenomyosis exhibit increased uterine hyperactivity, general…”
BackgroundLabrakakis, C., Rudolph, U., & Koninck, Y. D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00424 · Cited by 36
Self-citationZuiker, R. G. J. A., Chen, X., Østerberg, O., Mirza, N. R., Muglia, P., de Kam, M., Klaassen, E. S., & van Gerven, J. M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115620435 · Cited by 32
Shehab, S. A. S., Al-Marashda, K., AlZahmi, A., Abdul-Kareem, A., & Al-Sultan, M. A. H. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.089 · Cited by 29
Acupuncture: Emerging evidence for its use as an analgesic (Review)
Gao, P., Gao, X., Fu, T., Xu, D., & Wen, Q. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2348 · Cited by 27
Bravo‐Hernández, M., Feria-Morales, L. A., Torres‐López, J. E., Cervantes‐Durán, C., Delgado‐Lezama, R., Granados‐Soto, V., & Rocha-González, H. I. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.051 · Cited by 30
“V and within primary afferent terminals (Knabl et al., 2008; Paul et al., 2012).”
Fischer, B. D., Schlitt, R. J., Hamade, B. Z., Rehman, S., Ernst, M. C., Poe, M. M., Li, G., Kodali, R., Arnold, L. A., & Cook, J. M. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.03.001 · Cited by 31
Potential novel therapeutic strategies for neuropathic pain
Du, Z., Zhang, J., Han, X., Yu, W., & Gu, X. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1138798 · Cited by 34
Metadata
- Authors
- Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., Fritschy, J.-M., Rudolph, U., Möhler, H., & Zeilhofer, H. U.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Zurich (CH)
- University of Bonn (DE)
- Harvard University (US)
- Corresponding author
- Zeilhofer, Hanns Ulrich
- Venue
- Nature
- Published
- 2008-01
- Volume
- 451
- Issue
- 7176
- Pages
- 330-334
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2011606970
- Cited by
- 438
- References
- 43
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 13 · 2023: 10 · 2022: 15 · 2021: 22 · 2020: 24 · 2019: 17 · 2018: 23 · 2017: 21 · 2016: 27 · 2015: 33 · 2014: 27 · 2013: 38 · 2012: 38
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Keywords
- chronic pain, neuropathic pain, inflammatory pain, GABAA receptor subtypes, alpha2 subunit, alpha3 subunit, synaptic inhibition, dorsal horn, GABAergic neurotransmission, knock-in mice, analgesia, sedation, tolerance (pharmacology and immunology), pain-related brain activity
- MeSH terms
- Analgesics, Animals, Brain, Capsaicin, Chronic Disease, Diazepam, Disease Models, Animal, Fluorobenzenes, Formaldehyde, Ganglia, Spinal, Hot Temperature, Inflammation, Male, Neurons, Organ Specificity, Pain, Receptors, GABA-A, Spinal Cord, Triazoles, Rats, Wistar, Protein Isoforms, Protein Subunits, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.